Successfully identifying and targeting immune checkpoints on latently HIV-1-infected CD4+ T cells could be a key component in HIV-1 eradication therapies [1,2]. Immune checkpoints are negative regulators of: (i) T cell activation; (ii) T cell proliferation; and (iii) effector functions including cytokine production [3]. Thus, inhibiting immune checkpoints could influence the resting status of latently infected cells [1,2], which are key obstacles to curing HIV-1 [4,5]. Candidate immune checkpoints in this regard include programmed cell death-1 (PD-1), T cell immunoreceptor with immunoglobulin and ITIM-domains (TIGIT), lymphocyte-activating protein-3 (LAG-3) and type-1 transmembrane immunoglobulin and mucin-3 (TIM3) [1,2,6–8]. Antibodies blocking immune checkpoints have been hypothesised to disrupt the resting status of T cells and hence have been utilised as latency-reversing agents [5,7,9] and may enhance CD8+ T cell effector functions in HIV eradication trials [1,2,6–8].
We propose that distinguishing between total and memory CD4+ T cell subsets is fundamental when interpreting data regarding HIV-1 DNA and immune checkpoints. To ensure clarity: ‘total CD4+ T cells’ refers to all CD3+CD4+ lymphocytes and encompasses naïve and memory subsets; ‘memory CD4+ T cells’ includes the different memory subsets but excludes naïve cells (Figure 1a).
Figure 1.
PD-1 and TIGIT are primarily expressed on memory CD4+ T cells. (a) Definition of total and memory CD4+ T cells. (b–e) Flow cytometric characterisation of CD4+ T cell memory subsets and PD-1 and TIGIT expression (n=22). (b) Distribution of CD4+ T cell memory subsets. (c) PD-1 and TIGIT expression on naïve and memory (i.e. central memory, effector memory and terminally differentiated) CD4+ T cells. Statistics: Student's paired t-test. (d) Bar graph illustrating proportions of naïve and memory CD4+ T cells in all individuals. (e) PD-1 and TIGIT expression on total CD4+ T cells. (d, e) Individual data ranked according to percentage memory CD4+ T cells. (g–h) Graphical illustration of the coinciding correlation of (f) PD-1, (g) TIGIT and (h) HIV-1 DNA in total CD4+ T cells with the percentage of memory CD4+ T cells
Chomont et al. originally demonstrated that memory CD4+ T cells highly expressing PD-1 were enriched for HIV-1 DNA [2]. This key finding inspired others to examine immune checkpoint expression on CD4+ T cells and subsequent studies described a positive correlation between multiple immune check points (TIGIT, PD-1, LAG-3 or TIM-3) and HIV-1 DNA in total CD4+ T cells [10–12]. The rationale for examining immune checkpoints on total CD4+ T cells appears strong given that HIV-1 DNA in total CD4+ T cells is a crude but relatively reproducible approximation of the viral reservoir size. HIV-1 DNA also predicts time to viral rebound following analytical treatment interruption [13,14].
However, the original findings of Chomont et al. were from memory CD4+ T cells and subsequent studies have been from total CD4+ T cells. Therefore, we decided to analyse the expression of two immune checkpoints (PD-1 and TIGIT) on both total and memory CD4+ T cells in a cohort of 22 aviraemic HIV-infected individuals on long-term ART, to elucidate whether memory subset proportions could be a confounding factor when performing the analyses in total CD4+ T cells (cohort previously described [15]).
We found highly variable proportions of naïve and memory subsets between individuals (naïve CD4+ T cell range: 13–75%, Figure 1b) as previously published [16,17]. This variation exemplifies the heterogeneity in clinical cohorts encompassing HIV-infected individuals [18,19]. As also shown by others, we demonstrated that PD-1 and TIGIT are almost exclusively expressed on memory CD4+ T cells [2,8,16] (Figure 1c). To stress the importance of these findings, we ranked the 22 HIV-positive individuals according to the percentage of memory CD4+ T cells (low to high) (Figure 1d) and displayed the percentage of PD-1 or TIGIT-positive total CD4+ T cells for each individual (Figure 1e). These data demonstrated that a low proportion of memory CD4+ T cells corresponded to a low PD-1 or TIGIT expression on total CD4+ T cells, whereas a high proportion of memory CD4+ T cells corresponded to high PD-1 or TIGIT expression on total CD4+ T cells (Figures 1d, e). This linkage is substantiated by a highly significant positive correlation between the size of the memory CD4+ T cell compartment and the percentage of total CD4+ T cells expressing PD-1 or TIGIT (Figures 1f, g).
Adding our analytic approach to the current knowledge, two essential points should be stressed: (1) the majority of CD4+ T cells harbouring HIV-1 DNA are memory cells [2,20] (Figure 1h); and (2) a higher proportion of memory cells express immune checkpoints compared to naïve cells [2,8,16] (Figure 1c). The concomitant presence of HIV-1 DNA and immune checkpoints in memory CD4+ T cells means that the relative memory proportions could be a confounder when examining these parameters in total CD4+ T cells.
To explore the potential confounding effect of memory proportions, we investigated how the correlation between HIV-1 DNA and PD-1 or TIGIT change when performing the analysis in total CD4+ T cells versus memory CD4+ T cells (Figure 2). We demonstrated that HIV-1 DNA and percentage of total CD4+ T cells expressing PD-1 or TIGIT (Figure 2a) positively correlates as recently published [10–12]. However, correlating HIV-1 DNA and percentage of CD4+ T cells expressing PD-1 or TIGIT in memory CD4+ T cells results in different r-values compared to the analyses performed in total CD4+ T cells (Figures 2a–d). We estimated the magnitude of this change in r-value (Δr) using bootstrap analyses to estimate 95% confidence intervals (CI) and the permutation test to estimate P-values (Figure 2e). The difference in correlation for PD-1 (ΔrPD-1) and TIGIT (ΔrTIGIT) are, respectively, 0.496 (95% CI: 0.266–0.697; P=0.001) and 0.187 (95% CI: −0.059–0.542, P=0.1884; Figure 2e), demonstrating that memory subset proportion is a confounder when analysing potential immune checkpoint biomarkers for HIV-infected CD4+ T cells. These results imply that any correlation between HIV-1 DNA and immune checkpoints on total CD4+ T cells is largely driven by the proportions of memory versus naïve cells. Therefore, we argue that it cannot be inferred that CD4+ T cells expressing immune checkpoint are enriched for HIV-1 DNA based on analyses performed in total CD4+ T cells.
Figure 2.
Decision algorithm for evaluating PD-1 and TIGIT as biomarkers for HIV-infected cells. (a) Pearson correlation of HIV-1 DNA and PD-1 (left) or TIGIT (right) on total CD4+ T cells. (b and c) Two potential interpretations of the data depicted in (a). (d) Pearson correlation of PD-1 (left) or TIGIT (right) and HIV-1 DNA in memory CD4+ T cells (estimated by adjusting for the relative contribution of naïve CD4+ T cells for each individual as previously published [15]). (e) ΔrPD-1 and ΔrTIGIT estimated by bootstrap analyses for 95% confidence interval and permutation test for P-value
In conclusion, these data reveal the importance of quantifying individual memory subsets when analysing immune checkpoints on CD4+ T cells in order to evaluate their usage as biomarkers of infected cells or when defining candidate immune checkpoint(s) for targeting during HIV-1 eradication strategies.
Acknowledgements
We thank Henrik Støvring for biostatistical support.
References
- 1. DaFonseca S, Chomont N, El Far Met al. Purging the HIV-1 reservoir through the disruption of the PD-1 pathway. J Int AIDS Soc 2010; 13: O15– O15. [Google Scholar]
- 2. Chomont N, El-Far M, Ancuta Pet al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893– 900. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Chen L, Flies DB.. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13: 227– 242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Eisele E, Siliciano RF.. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012; 37: 377– 388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Rasmussen TA, Tolstrup M, Sogaard OS.. Reversal of latency as part of a cure for HIV-1. Trends Microbiol 2015; 24: 90– 97. [DOI] [PubMed] [Google Scholar]
- 6. Porichis F, Kaufmann DE.. Role of PD-1 in HIV pathogenesis and as target for therapy. Curr HIV/AIDS Rep 2012; 9: 81– 90. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Barouch DH, Deeks SG.. Immunologic strategies for HIV-1 remission and eradication. Science 2014; 345: 169– 174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Fromentin R, Bakerman W, Lawani Met al. The immune checkpoints PD-1, LAG-3 and TIGIT are biomarkers of HIV infected cells during ART and identify distinct cellular reservoirs. Towards an HIV Cure Symposium. July 2014. Sydney, Australia.
- 9. Chun TW, Moir S, Fauci AS.. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol 2015; 16: 584– 589. [DOI] [PubMed] [Google Scholar]
- 10. Hurst J, Hoffmann M, Pace Met al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun 2015; 6: 8495. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Chew GM, Fujita T, Webb GMet al. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection. PLoS Pathog 2016; 12: e1005349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Hatano H, Jain V, Hunt PWet al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis 2013; 208: 50– 56. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Williams JP, Hurst J, Stohr Wet al. HIV-1 DNA predicts disease progression and post-treatment virological control. Elife 2014; 3: e03821. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Rasmussen TA, Tolstrup M, Brinkmann CRet al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 2014; 1: e13– e21. [DOI] [PubMed] [Google Scholar]
- 15. Leth S, Nymann R, Jørgensen Set al. HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on ART. AIDS 2015; 30: 713– 721. [DOI] [PubMed] [Google Scholar]
- 16. Breton G, Chomont N, Takata Het al. Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection. J Immunol 2013; 191: 2194– 2204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Rosignoli G, Lim CH, Bower Met al. Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Clin Exp Immunol 2009; 157: 90– 97. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Robbins GK, Spritzler JG, Chan ESet al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48: 350– 361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Sakai K, Gatanaga H, Takata Het al. Comparison of CD4(+) T-cell subset distribution in chronically infected HIV(+) patients with various CD4 nadir counts. Microbes Infect 2010; 12: 374– 381. [DOI] [PubMed] [Google Scholar]
- 20. Buzon MJ, Sun H, Li Cet al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med 2014; 20: 139– 142. [DOI] [PMC free article] [PubMed] [Google Scholar]


